BB&T Capital Cuts PT on Foot Locker (FL) Following Nike 4Q Report, But Incrementally Positive
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
UBS Remains Bullish on Nike (NKE) Following 4Q Report
June 29, 2016 7:55 AM EDTUBS reiterated a Buy rating and $70.00 price target on Nike (NYSE: NKE) following the company's 4Q earnings report. NKE reported EPS at $0.49, in line with UBS estimates, and $0.01 above the Street. Revenues missed estimates by only -1%.
Analyst Michael Binetti commented, "NKE reported F4Q EPS... More
BB&T Capital Reiterates Buy on Nike (NKE) Following 4Q Beat
June 29, 2016 7:27 AM EDTBB&T Capital reiterated a Buy rating and $70.00 price target on Nike (NYSE: NKE) following the company's 4Q earnings report. NKE reported a slight $0.01 EPS beat compared to Street estimates. Reported revenue grew +6%, largely in line with estimates, driven by +DD ex-Fx growth in... More
After-Hours Stock Movers 06/28: (KMPH) (FUEL) Higher; (ESPR) (NKE) (ANTH) Lower (more...)
June 28, 2016 5:55 PM EDTToday's After-Hours Movers:
Esperion Therapeutics, Inc. (NASDAQ: ESPR) 25.2% LOWER; provided updates on the bempedoic acid (ETC-1002) clinical development program and regulatory plans... For the United States (U.S.), the Company engaged with the U.S. Food and Drug Administration (FDA or the Agency) resulting in alignment on the definition of statin intolerance, key design features of the CVOT, and the regulatory approval pathway for a CV disease risk reduction indication in statin intolerant patients for bempedoic acid. However, the FDA did not provide clarity on a... More
